Characterisation of GEA 3175 on human platelets; comparison with S-nitroso-N-acetyl-D,L-penicillamine

European Journal of Pharmacology

Volumn 496, Issue 1, 2004, Pages 1-9

  Asplund Persson, Anna K ^a   Palmér, Louise ^a   Gunnarsson, Peter ^a   Grenegård, Magnus ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Aggregation; Calcium; cGMP (cyclic guanosine 3 ,5 monophosphate); GEA 3175; NO (Nitric Oxide); Platelet; SNAP (S nitroso N acetyl D,L penicillamine)

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 3 (3 CHLORO 2 METHYLPHENYL) 5 (4 METHYLBENZENESULFONYLIMINO) 1,2,3,4 OXATRIAZOLE; CALCIUM; CYCLIC GMP; GUANYLATE CYCLASE INHIBITOR; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; THROMBIN;

ARTICLE; CALCIUM CELL LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFECT; HUMAN; HUMAN CELL; INCUBATION TIME; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE;

BLOOD PLATELETS; CYCLIC GMP; HUMANS; NITRIC OXIDE; S-NITROSO-N-ACETYLPENICILLAMINE; TRIAZOLES;

EID: 3543134315     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.06.002     Document Type: Article

References (25)

1. Ahlner J., Andersson R.G., Axelsson K.L., Bunnfors I., Wallentin L. Effects of dipyridamole on the glyceryl-trinitrate-induced inhibition of coronary artery muscle tone and platelet aggregation in relation to cyclic nucleotide metabolism. Acta Pharm. Toxicol. (Cph.). 57:1985;88-95
2. Aszüdi A., Pfeifer A., Ahmad M., Glauner M., Zhou X.-H., Ny L., Andersson K.-E., Kehrel B., Offermanns S., Fässler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 18:1999;37-48
3. Axelsson K.L., Bornfeldt K.E., Norlander B., Wikberg J.E.S. Attomole sensitive radioimmunoassay for cyclic GMP. Second Messengers Phosphoprot. 12:1988;145-154
4. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376
5. Grenegård M., Gustafsson M.C., Andersson R.G.G., Bengtsson T. Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide-donor GEA 3175 and adenosine. Br. J. Pharmacol. 118:1996;2140-2144
6. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450
7. Hernandez M., Elmedal B., Mulvany M.J., Simonsen U. Mechanisms of relaxations of bovine isolated bronchioles by the nitric oxide donor, GEA 3175. Br. J. Pharmacol. 123:1998;895-905
8. Ignarro L.J., Napoli C., Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. 90:2002;21-28
9. Johansson Rydberg I.G.M., Andersson R.G.G., Grenegård M. Effects of the nitric oxide donor, GEA 3175, on guinea-pig airways. Eur. J. Pharmacol. 329:1997;175-180
10. Kankaanranta H., Rydell, Petersson E., Holm A.-S., Moilanen P.E., Corell T., Karup G., Vuorinen P., Pedersen S.B., Wennmalm Å., Metsä-Ketelä T. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives. Br. J. Pharmacol. 117:1996;401-406
11. Karup G., Preikschat H., Wilhelmsen E.S., Pedersen S.B., Marcinkiewicz E., Cieslik K., Gryglewski R.J. Mesoionic oxatriazole derivatives - a new group of NO-donors. Pol. J. Pharmacol. 46:1994;541-552
12. Kosonen O., Kankaanranta H., Vuorinen P., Moilanen E. Inhibition of human lymphocyte proliferation by nitric oxide-releasing oxatriazole derivatives. Eur. J. Pharmacol. 337:1997;55-61
13. Kosonen O., Kankaanranta H., Uotila J., Moilanen E. Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells. Eur. J. Pharmacol. 394:2000;149-156
14. Lahteenmaki T., Sievi E., Vapaatalo H. Inhibitory effects of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives on vascular smooth muscle cell mitogenesis and proliferation in vitro. Br. J. Pharmacol. 125:1998;402-408
15. Martin D.D., Tong J.S., Parker J.D. Platelet cyclic GMP responses to nitroglycerin. Cardiovasc. Drugs Ther. 14:2000;419-425
16. Megson I.L. Nitric oxide donor drugs. Drugs of the Future. vol. 25:2000;701-715. (http://www.prous.com)
17. Moro M.A., Russel R.J., Cellek S., Lizasoain I., Su Y., Darley-Usmar V.M., Radomski M.W., Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1480-1485
18. Mullershausen F., Russwurm M., Thompson W.J., Liu L., Koesling D., Friebe A. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J. Cell Biol. 155:2001;271-278
19. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526
20. Radomski M.W., Palmer R.M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92:1987;639-646
21. Radomski M.W., Palmer R.M., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1987;1057-1058
22. 2+. Biochem. J. 258:1989;923-926
23. Schwarz U.R., Walter U., Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem. Pharmacol. 62:2001;1153-1161
24. Torfgard K.E., Ahlner J. Mechanisms of action of nitrates. Cardiovasc. Drugs Ther. 8:1994;701-717
25. Walter U., Eigenthaler M., Geiger J., Reinhard M., Authi K.S., Watson S.P., Kakkar E.V.V. Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. Mechanisms of Platelet Activation and Control. 1993;237-249 Plenum Press, New York